Vedolizumab therapy for inflammatory bowel disease (Homo sapiens)
From WikiPathways
Description
"Vedolizumab is a humanized monoclonal antibody with a predominantly gastrointestinal effect. It specifically inhibits leucocyte integrin α4β7, thus preventing its interaction with mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), which is involved in the migration of lymphocytes from the blood stream to the intestinal tissue. Vedolizumab is indicated in the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adult patients with poor response, loss of response, or intolerance to conventional treatment or to tumour necrosis factor alpha (TNF-α) antagonists." Inspired by Figure 1 in https://pubmed.ncbi.nlm.nih.gov/31470005/. Vedolizumab is also known by its trade name, Entyvio.
Quality Tags
Ontology Terms
Pathway Ontology : disease pathway
Disease : familial chylomicronemia syndrome congenital generalized lipodystrophy type 4 congenital generalized lipodystrophy type 3 hyperlipoproteinemia type V familial hyperlipidemia lipodystrophy familial partial lipodystrophy type 1 hyperlipoproteinemia type III congenital generalized lipodystrophy type 1 lipid metabolism disorder familial hypercholesterolemia hypolipoproteinemia familial partial lipodystrophy type 2 familial partial lipodystrophy type 6 acquired generalized lipodystrophy congenital generalized lipodystrophy type 2 familial partial lipodystrophy type 3 familial partial lipodystrophy type 4 familial partial lipodystrophy type 5 hyperlipoproteinemia type IV familial combined hyperlipidemia abetalipoproteinemia Norum disease Tangier disease
Bibliography
- Eugeni Domenecha, Javier P. Gisbert; ''Efficacy and safety of vedolizumab in the treatment of ulcerative colitis''; Gastroenterologia y Hepatologia, 2016
History
View all... |
External references
DataNodes
View all... |
Name ![]() | Type ![]() | Database reference ![]() | Comment ![]() |
---|---|---|---|
ICAM1 | GeneProduct | ENSG00000090339 (Ensembl) ![]() | |
ITGA2 | GeneProduct | ENSG00000164171 (Ensembl) ![]() | |
ITGA4 | GeneProduct | ENSG00000115232 (Ensembl) ![]() | |
ITGB1 | GeneProduct | ENSG00000150093 (Ensembl) ![]() | |
ITGB2 | GeneProduct | ENSG00000160255 (Ensembl) ![]() | |
ITGB7 | GeneProduct | ENSG00000139626 (Ensembl) ![]() | |
MADCAM1 | GeneProduct | ENSG00000099866 (Ensembl) ![]() | |
SELE | GeneProduct | ENSG00000007908 (Ensembl) ![]() | |
SELPLG | GeneProduct | ENSG00000110876 (Ensembl) ![]() | |
VCAM1 | GeneProduct | ENSG00000162692 (Ensembl) ![]() | |
Vedolizumab | Metabolite | DB09033 (DrugBank) ![]() |
Annotated Interactions
No annotated interactions